



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



### Description

Fc Gamma Receptor 2A (also known as CD32A, Fc-gamma-RIIa, FcγRIIa) is a low affinity Fc receptor for immunoglobulin G, encoded by the FCGR2A gene. Fc Gamma Receptor 2A is a cell surface receptor that is expressed on a variety of immune cells such as macrophages and neutrophils. It is involved in phagocytosis and in the clearing of spent immune complexes from the circulation. A polymorphism in FCGR2A has been associated with increased risks of nephritis and lupus.

The FCGR2A CRISPR/Cas9 Lentiviruses are replication incompetent, HIV-based VSV-G pseudo-typed lentiviral particles that are ready to transduce into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 5 sgRNA (single guide RNA) targeting human FCGR2A (Figure 1 and Table 1).




Figure 1: Schematic of the lenti-vector used to generate the FCGR2A CRISPR/Cas9 Lentivirus.

Gene Target:	sgRNA Sequence:
FCGR2A-1-F	TGGAGCACGTTGATCCACGG
FCGR2A-2-F	AGGGAGAAACCATCATGCTG
FCGR2A-3-F	GCTTGTGGGATGGAGAAGGT
FCGR2A-4-F	AGCAGCAGCAAACTGTCAA
FCGR2A-5-F	AAAGCACAGTCAGATGCACA

Figure 2: List of sgRNA Sequences in the FCGR2A CRISPR/Cas9 Lentivirus.

### Application(s)

- Transient knockdown of FCGR2A in target cells
- Generation of a stable FCGR2A knockout cell line following puromycin selection and limiting dilution

### Formulation

The lentivirus particles were produced from HEK293T cells. They are supplied in cell culture medium containing 90% DMEM + 10% FBS.

### Titer

Two vials (500  $\mu$ l x 2) of lentivirus at a titer  $\geq 1 \times 10^7$  TU/ml. The titer will vary with each lot; the exact value is provided with each shipment.

### Storage




Lentiviruses are shipped with dry ice. For long-term storage, it is recommended to store the lentiviruses at  $-80^{\circ}\text{C}$ . Avoid repeated freeze-thaw cycles. Titers can drop significantly with each freeze-thaw cycle.

### Biosafety



The lentiviruses are produced with the SIN (self-inactivation) lentivector which ensures self-inactivation of the lentiviral construct after transduction and after integration into the genomic DNA of the target cells. None of the HIV genes (gag, pol, rev) will be expressed in the transduced cells, as they are expressed from packaging plasmids lacking the packing signal and are not present in the lentivirus particle. Although the pseudotyped lentiviruses are replication-incompetent, they require the use of a Biosafety Level 2 facility. BPS Bioscience recommends following all local federal, state, and institutional regulations and using all appropriate safety precautions.

### Validation Data



*Figure 3: Knockdown of FCGR2A in Jurkat cells using FCGR2A CRISPR/Cas9 Lentivirus.*

Jurkat cells were transduced via spinoculation with  $1 \times 10^7$  TU/well of FCGR2A CRISPR/Cas9 lentivirus, corresponding to an MOI  $>5$ . 48 hours after transduction, cells were stained with CoraLite 488-conjugated FCGR2A antibody (ThermoFisher #CL488-66529) and analyzed by flow cytometry. Non-transduced, parental Jurkat cells are shown in blue, and the transduced cells are shown in green.

**Troubleshooting Guide**

Visit [bpsbioscience.com/lentivirus-faq](https://bpsbioscience.com/lentivirus-faq) for detailed troubleshooting instructions. For all further questions, please email [support@bpsbioscience.com](mailto:support@bpsbioscience.com).

**Notes**

The CRISPR/CAS9 technology is covered under numerous patents, including U.S. Patent Nos. 8,697,359 and 8,771,945, as well as corresponding foreign patents applications, and patent rights.

**Related Products**

<i>Products</i>	<i>Catalog #</i>	<i>Size</i>
CTLA4 CRISPR/Cas9 Lentivirus (Non-Integrating)	78061	500 µl x 2
CTLA4 CRISPR/Cas9 Lentivirus (Integrating)	78054	500 µl x 2
TIGIT CRISPR/Cas9 Lentivirus (Non-Integrating)	78065	500 µl x 2
TIGIT CRISPR/Cas9 Lentivirus (Integrating)	78058	500 µl x 2
CD47 CRISPR/Cas9 Lentivirus (Non-Integrating)	78063	500 µl x 2
CD47 CRISPR/Cas9 Lentivirus (Integrating)	78056	500 µl x 2